SGLT inhibitors in management of diabetes

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 2, 2013, Pages 140-151

  Tahrani, Abd A ^a,b   Barnett, Anthony H ^a,b   Bailey, Clifford J ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BUMETANIDE; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; HYDROCHLOROTHIAZIDE; INSULIN; IPRAGLIFLOZIN; KGA 2727; LX 4211; LX 4221; METFORMIN; METFORMIN PLUS PIOGLITAZONE; PHLORIZIN; PIOGLITAZONE; PLACEBO; RIFAMPICIN; SIMVASTATIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; SULFONYLUREA; TOFOGLIFLOZIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VOGLIBOSE; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER;

ADD ON THERAPY; AREA UNDER THE CURVE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CEREBROVASCULAR ACCIDENT; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; INTESTINE; KIDNEY; METABOLISM;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINES; KIDNEY; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 84884502673     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70050-0     Document Type: Review

References (86)

1. DeFronzo RA From triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
2. Bailey CJ The challenge of managing coexistent type 2 diabetes and obesity. BMJ 2011, 342:d1996. 10.1136/bmj.d1996.
3. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378:182-197.
4. Hediger MA, Rhoads DB Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994, 74:993-1026.
5. Wright EM, Loo DDF, Hirayama BA Biology of human sodium glucose transporters. Physiol Rev 2011, 91:733-794.
6. Bell GI, Kayano T, Buse JB, et al. Molecular biology of mammalian glucose transporters. Diabetes Care 1990, 13:198-208.
7. Wright EM, Hirayama BA, Loo DF Active sugar transport in health and disease. J Intern Med 2007, 261:32-43.
8. Shirazi-Beechey SP, Moran AW, Batchelor DJ, Daly K, Al-Rammahi M Glucose sensing and signalling; regulation of intestinal glucose transport. Proc Nutrition Soc 2011, 70:185-193.
9. Stümpel F, Burcelin R, Jungermann K, Thorens B Normal kinetics of intestinal glucose absorption in the absence of GLUT2: evidence for a transport pathway requiring glucose phosphorylation and transfer into the endoplasmic reticulum. Proc Natl Acad Sci USA 2001, 98:11330-11335.
10. Gorboulev V, Schlormann A, Vallon V, et al. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012, 61:187-196.
11. Margolskee RF, Dyer J, Kokrashvili Z, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 2007, 104:15075-15080.
12. Dyer J, Wood IS, Palejwala A, Ellis A, Shirazi-Beechey SP Expression of monosaccharide transporters in intestine of diabetic humans. Amer J Physiol Gastrointest Liver Physiol 2002, 282:G241-G248.
13. Schneider AJ, Kinter WB, Stirling CE Glucose-Galactose Malabsorption. N Engl J Med 1966, 274:305-312.
14. Gerich JE Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Med 2010, 27:136-142.
15. Gerich JE, Meyer C, Woerle HJ, Stumvoll M Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001, 24:382-391.
16. +/glucose cotransporters in renal proximal tubule cells. Kidney Int 2007, 72:S27-S35.
17. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54:3427-3434.
18. Vallon V The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 2011, 300:R1009-R1022.
19. Santer R, Calado J Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010, 5:133-141.
20. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987, 79:1510-1515.
21. Ehrenkranz JR, Ehrenkranz JR, Lewis NG, Kahn CR, Roth J Phlorizin: a review. Diabetes Metab Res Rev 2005, 21:31-38.
22. DeFronzo RA, Davidson JA, Del Prato S The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012, 14:5-14.
23. Bailey CJ Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011, 32:63-71.
24. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008, 51:1145-1149.
25. Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophenerRing, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010, 53:6355-6360.
26. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 14:83-90.
27. Imamura M, Nakanishi K, Suzuki T, et al. Discovery of ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 2012, 20:3263-3279.
28. Ohtake Y, Sato T, Kobayashi T, et al. Discovery of tofogliflozin, a novel C-aryl glucoside with a)-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012, 55:7828-7840.
29. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Disp 2013, 41:445-456.
30. Zanardi TA, Han SC, Jeong EJ, et al. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther 2012, 34:489-496.
31. Bailey CJ, Day C SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis 2010, 10:193-199.
32. Liu J, Lee T, DeFronzo RA Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans. Diabetes 2012, 61:2199-2204.
33. Shibazaki T, Tomae M, Ishakawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2012, 34:288-296.
34. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012, 92:158-169.
35. Dapagliflozin (Forxiga), summary of product characteristics, Bristol-Myers Squibb, Uxbridge, UK, November 2012 (accessed April 1, 2013). http://www.medicines.org.uk/EMC/medicine/27188/.
36. Kasichayanula S, Liu X, Benito MP, et al. The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2012, published online Dec 4. 10.1111/bcp.12056.
37. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther 2011, 33:1798-1808.
38. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011, 13:47-54.
39. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Therapy 2012, 29:163-177.
40. Kasichayanula S, Liu X, Griffen SC, LaCreta FP, Boulton DW Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab 2013, 15:280-283.
41. FDA Endocrinologic and Metabolic Drugs Advisory Committee. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. JNJ-28431754 (Canagliflozin). NDA 204042. January 10, 2013.
42. Macha S, Mattheus M, Pinnetti S, Seman L, Woerle J Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. J Diabetes Res Clin Metab 2012, 1:1-14.
43. Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 2012, 29:889-899.
44. Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013, 35:A33-A42.
45. Macha S, Dieterich S, Mattheus M, Seman LJ, Broedl UC, Woerle HJ Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther 2012, 51:132-140.
46. Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2013, 15:316-323.
47. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013, 15:613-621.
48. Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Invest 2011, 31:839-851.
49. Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab 2012, 14:937-943.
50. Schwab D, Portron A, Backholer Z, Lausecker B, Kawashima K A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C] tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C] tofogliflozin in humans. Clin Pharmacokinet 2013, 52:463-473.
51. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012, 92:158-169.
52. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M Dapagliflozin, a novel selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:520-526.
53. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. Diabetes Care 2013, 36:2154-2161.
54. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces the calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011, 13:669-672.
55. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev 2013, published online Mar 27. 10.1002/cpdd.16.
56. List JF, Woo V, Morales E, Tang W, Fiedorek FT Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32:650-657.
57. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
58. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011, 34:2015-2022.
59. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656-1662.
60. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF Dapagliflozin monotherapy in type 2 diabetic patients pith inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010, 33:2217-2224.
61. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011, 13:928-938.
62. 1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012, 35:1473-1478.
63. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Prac 2012, 66:446-456.
64. Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. A randomized trial. Ann Intern Med 2012, 156:405-415.
65. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010, 12:510-516.
66. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012, 97:1020-1031.
67. Bailey CJ, Iqbal N, T'joen C, List JF Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obesity Metab 2012, 14:951-959.
68. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomised, double-blind, placebo-controlled 102-week trial. BMC Med 2013, 11:43.
69. Clar C, Gill JA, Court R, Waugh N Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012, 2.
70. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012, 35:1232-1238.
71. Nicolle LE, Capuano G, Ways K, Usiskin K Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012, 28:1167-1171.
72. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012, 14:539-545.
73. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382.
74. Schernthaner G, Gross JL, Rosenstack J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care 2013, published online April 5. 10.2337/dc12-2491.
75. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ A hhase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013, 15:721-728.
76. Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 2013, 27:268-273.
77. Wilding JPH, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2013, 15:403-409.
78. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Therap 2013, 35:273-285.
79. Ferrannini E, Solini A SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012, 8:495-502.
80. Foote C, Perkovic V, Neal B Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012, 9:117-123.
81. Bailey CJ Interpreting adverse signals in diabetes drug development programs. Diabetes Care 2013, 36:2098-2106.
82. Dapagliflozin background document US Food and Drug Administration Endocrinologic and metabolic advisory committee, (accessed July 31, 2013). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262996.pdf.
83. Plosker GL Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012, 72:2289-2312.
84. Shah NK, Deeb WE, Choksi R, Epstein BJ Dapagliflozin: a novel sodium-glucose co-transporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012, 32:80-94.
85. Barnett AH, Ali O, Bailey CJ, et al. Recommendations regarding the position of dapagliflozin within the type 2 diabetes treatment algorithm. Diabetes Prac 2013, 2:1-11.
86. Bailey CJ, Day C Diabetes therapies in renal impairment. Br J Diabetes Vasc Dis 2012, 12:167-171.